2024 Annual Meeting - Agenda

This session will provide an overview of the echocardiographic evaluation of aortic stenosis in the pre-, intra-, and post-procedure settings. Acquiring key images, making accurate measurements, grading stenosis severity, and detecting procedural complications will be reviewed.

• Review the echocardiographic evaluation of aortic stenosis
• Grade the severity of aortic stenosis
• Detect and evaluate complications post aortic valve intervention

Fetal Aortic Valvuloplasty: Promoting Left Ventricular Growth in Evolving Hypoplastic Left Heart Syndrome.

• Understand fetal circulation and how alterations associated with congenital heart disease affects cardiac growth
• Discuss indications and patient selection criteria for fetal aortic valvuloplasty
• Describe outcomes of fetal aortic valvuloplasty with postnatal evaluation and follow up

• Discuss the current role of cardiac CT in TAVR procedure, patients and devices selection
• Discuss the current role of cardiac CT in TMVR procedure, patients and devices selection
• Discuss the current role of cardiac CT in LAAO procedure, patients and devices selection

Triumph over cardiac amyloidosis: the importance of multidisciplinary approach to Cardiac Amyloid.

• Highlight the Importance of cardiac Amyloid management with multidisciplinary approach
• Describe the University of Kentucky Amyloid Alliance
• Describe the roles of various specialists of the amyloid alliance in diagnosis and management of cardiac amyloidosis

This session aims to provide an in-depth understanding of the complex interplay between Heart Failure with preserved Ejection Fraction (HFpEF), frailty, and malnourishment. Participants will gain insights into the pathophysiology, clinical features, diagnostic criteria, and management strategies for HFpEF in patients who are frail and malnourished. Through case studies, interactive discussions, and evidence-based approaches, healthcare providers will learn to optimize care for this vulnerable patient population.

• Understand the relationship between HFpEF and frailty/malnourishment
• Identify the clinical features and diagnostic criteria for HFpEF in patients with frailty and malnourishment
• Evaluate the management strategies and treatment options for patients with HFpEF and concurrent frailty and malnourishment

During this session we will review the clinical course of a patient with both ATTR and AL amyloidosis who received a dual organ transplant. We will review pre and post transplant care in patients with amyloidosis and discuss the importance of a multi-disciplinary approach.

• Understand the importance of a multidisciplinary approach in the evaluation of amyloidosis
• Review pre-transplant evaluation and preparation in patients with amyloidosis
• Learn about postoperative care and long-term management strategies in patients with amyloidosis

With more adults living with chronic health conditions and the expansion of medications focused on treatment and prevention of these conditions, the cardiology community is more focused on cardiometabolic disease and chronic health management. The use of glucagon-like peptide-1 receptor and gastric inhibitory polypeptide receptor agonists are growing in popularity, not only for diabetes management, but also weight management and cardiovascular risk reduction. While more cardiology clinicians are prescribing these agents recently, diabetes clinicians have been utilizing these agents for over a decade. It is important to appreciate the clinical experience, efficacy data, and safety profiles for these agents for our patients.

• Describe the indications and efficacy data for use of GLP1R and GIP agonists
• Evaluate the safety profiles for incretin mimetics to support safe and effective prescribing
• Appreciate clinical practice pearls to improve patient response and tolerance to incretin mimetics

Identification and treatment of HFpEF mimics and safety considerations with treatment of certain HFpEF mimics.

• Discuss HFpEF definition, diagnosis, and treatment
• Identify and describe the definition, diagnosis, and treatment of certain cardiac HFpEF mimics
• Describe the adverse events and safety considerations with treatment of HFpEF mimics

Human Epidermal Growth Factor Receptor-2 (HER2) targeted therapies are common treatments used to manage and treat several oncologic malignancies. Since the approval of trastuzumab in 1998, patients with HER2-positive breast cancer have lived longer; however, the risk for adverse cardiac events has increased in patients treated with trastuzumab.

• Explain the pathophysiologic mechanism of HER2-targeted cardiotoxicity
• Describe risk stratification tools for HER2-targeted cardiotoxicity and monitoring protocols for such cardiotoxicity
• Discuss management strategies to prevent HER2-targeted cardiotoxicity

• Review which patients undergo the Fontan operation and its surgical variations
• Review long-term outcomes in patients s/p Fontan, including arrhythmias and heart failure
• Review noninvasive and invasive management strategies for Fontan patients with arrhythmias and HF

Atrial fibrillation (AF) and heart failure (HF) frequently coexist. Both are associated with significant morbidity and mortality. Appropriate AF management in HF can significantly improve outcomes.

• To recognize impact of AF on HF management
• To acknowledge possible benefits of maintaining normal sinus rhythm in patients with AF
• To acknowledge possible benefits of maintaining normal sinus rhythm in patients with HF

Ventricular tachycardia diagnosis and management for the non EP.

• Understand role of new medications to treat EP
• Be aware of role of stellate ganglion block in management of VT storm
• Be aware of new technologies in pipeline that may change VT ablation

• Review the patient selection criteria, technical considerations, and clinical data for ICD and CRT
• Examine the clinical benefits of left bundle pacing in comparison to CRT therapy
• Explore the potential roles of other devices, including CCM and autonomic modulation

This session will delve into the latest chest pain guidelines, emphasizing the pivotal role of coronary CT angiography (CTA) and fractional flow reserve CT (FFRCT). Attendees will gain insights into how these advanced imaging modalities enhance diagnostic accuracy, guide treatment decisions, and improve patient outcomes in the management of chest pain.

• Review the latest guidelines for the evaluation and management of chest pain, with a focus on how these guidelines incorporate the use of coronary CT angiography (CTA) and fractional flow reserve CT (FFRCT)
• Analyze the role of coronary CTA in the diagnosis and risk stratification of patients presenting with chest pain, including its accuracy, diagnostic capabilities, and integration into clinical practice

Advanced Cardiac Imaging in General Clinical Practice.

• Understand the Role of Advanced Cardiac Imaging (Coronary CTA and Cardiac MRI) in the Assessment of Coronary Artery Disease and Cardiomyopathy
• Identify Appropriate Use and Guideline Indications for the Utilization and Implementation of Coronary CTA and Cardiac MRI in Clinical Practice
• Integrate Coronary CTA and Cardiac MRI into Clinical Decision-Making for Risk Stratification and Prognostication

Various non-invasive imaging modalities are available for evaluating patients with ischemic heart disease. This session focuses on the use of cardiac PET in ischemic heart disease.

• Discuss differences between SPECT and PET for evaluation of IHD
• Understand the use of PET in evaluating patients with suspected IHD
• Demonstrate the utility of cardiac PET through case illustrations

Explore critical aspects of initiating Sotatercept therapy with an emphasis on the referral process, the initial treatment phase and the nursing role in preventing treatment delays and minimizing patient harm.

• Provide an overview of Sotatercept, highlighting its unique mechanism of action and potential impact on patient outcomes
• Discuss the importance of patient education to streamline the referral process and enhance patient adherence
• Outline the critical role of clear team communication with regards to preventing treatment delays and minimizing patient harm

Pediatric pulmonary hypertension definition, diagnostic algorithm, and treatment – updates from the 2024 World Symposium.

• Define pulmonary hypertension in a pediatric patient
• Review the diagnostic algorithm and risk stratification for children with PH
• Describe the current treatment practices for children with PH